May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
The Effect of Sertraline on Ambulatory Blood Pressure and Ocular Perfusion Pressure in Normotensive Glaucoma Patients With Nocturnal Hypotension
Author Affiliations & Notes
  • N. Yildirim
    Department Of Ophthalmology, Eskisehir, Eskisehir Osmangazi University, Medical School, Turkey
  • H. Basmak
    Department Of Ophthalmology, Eskisehir, Eskisehir Osmangazi University, Medical School, Turkey
  • A. Sahin
    Department Of Ophthalmology, Eskisehir, Eskisehir Osmangazi University, Medical School, Turkey
  • Z. Ermis
    Anadolu Hospital, Eskisehir, Turkey
  • Footnotes
    Commercial Relationships  N. Yildirim, None; H. Basmak, None; A. Sahin, None; Z. Ermis, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 484. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. Yildirim, H. Basmak, A. Sahin, Z. Ermis; The Effect of Sertraline on Ambulatory Blood Pressure and Ocular Perfusion Pressure in Normotensive Glaucoma Patients With Nocturnal Hypotension . Invest. Ophthalmol. Vis. Sci. 2006;47(13):484.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effect of sertraline on ambulatory blood pressure, and ocular perfusion pressure in normotensive glaucoma (NTG) patients with nocturnal hypotension.

Methods: : A total of 12 NTG patients (6 females, 6 males) with nocturnal hypotension were enrolled. All patients underwent complete ophthalmologic examination and 24 hour ambulatory blood pressure monitoring. Patients were further classified as dipper and non–dipper according to difference between systolic and diastolic blood pressures. Ophthalmic artery flow rate was measured in daytime and nighttime by using Duplex ultrasonography. Ocular blood perfusion pressure (OBPP) was calculated using a special formula (OBPP=1/3*mean arterial pressure–IOP). 50 mg sertraline was given twice a day to all study patients for two months time. All measurements were performed respectively after 2 months later.

Results: : The mean patient age was 52.2 ± 11.4 years. Before sertraline treatment, mean systolic and diastolic blood pressure values in daytime were 122.0±11.9 and 75.6±7,0 mmHg, in nighttime were 98.8±7.9 and 60.8±5.9 mmHg, respectively. Daytime and nighttime difference was 23.2 mmHg in systole and 14.8 mmHg in diastole. Of the 12 patients, 7 patients have got over–dipper type blood pressure and 5 patients have got dipper type blood pressure. After 2 months sertraline treatment, mean systolic and diastolic blood pressure values in daytime were 116.2±11.7 and 73.4±7.6 mmHg, in nighttime were 107.3±11.2 and 65.6±7.9 mmHg, respectively. Daytime and nighttime difference was 8.9 mmHg in systole and 7.8 mmHg in diastole. Mean systolic blood pressure in daytime decreased significantly (t=2.42, p<0.05) with sertraline treatment but mean diastolic blood pressure did not change significantly (t=1.2, p<0.05). Mean systolic and diastolic blood pressure measured in nighttime increased significantly after sertraline treatment(t=–3.75 and t=–3.22, respectively. All p<0.01). Mean differences between systolic and diastolic blood pressures in daytime and nighttime decreased significantly (p<0.01). Ophthalmic artery flow rates OBPP, and IOP readings in daytime and nighttime did not change significantly with sertraline treatment.

Conclusions: : Sertraline treatment improved nocturnal hypotension in NTG patients by decreasing the measured blood pressure difference between daytime and nighttime. However, no effect was observed on ophthalmic artery flow rate, OBPP, and IOP.

Keywords: blood supply • circadian rhythms • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×